Cam5.2 |
0/1(breast)1, 0/1(pancreas)3, 0/1(base
of skull, malignant)7 |
|
AE1/3 |
0/1(breast)1, 0/1(pancreas)3, 0/1(base
of skull, malignant)7,
3/23(5-25%
of cells)12 |
KL1 |
0/1(pancreas)3 |
Pancytokeratin |
0/1(common
bile duct)6,
0/1(subcutis
over knee, malignant)8,
0/1(malignant
rectovaginal tumour: biphasic tumour composed of spindle cell
and epithelioid components)9 |
CK7 |
0/1(base
of skull, malignant)7 |
Desmin |
0/1(breast)1, 0/1(base
of skull, malignant)7,
0/1(subcutis
over knee, malignant)8,
1/1(malignant
rectovaginal tumour: biphasic tumour composed of spindle cell
and epithelioid components: spindle cell component weakly positive)9, 0/1(uterus)10, 8/22(>50%
of cells: 3 cases, 25-50% of cells: 1 case, 5-25% of cells: 4
cases)12 |
Muscle-specific actin |
0/1(breast)1, 0/1(base
of skull, malignant, equivocal staining of a few cells)7, 1/1(malignant
rectovaginal tumour: biphasic tumour composed of spindle cell
and epithelioid components: spindle cell component moderately
positive)9 |
SMA |
0/1(breast)1, 0/1(common
bile duct)6,
1/1(base
of skull, malignant, scattered cells positive)7,
1/1(subcutis
over knee, malignant: variable, focally strong positivity)8, 1/1(malignant
rectovaginal tumour: biphasic tumour composed of spindle cell
and epithelioid components: spindle cell component strongly positive)9, 0/1(uterus)10, 20/25(>50%
of cells: 7 cases, 25-50% of cells: 5 cases, 5-25% of cells: 9
cases : positivity was greater in epithelioid than in spindle
cells) 12 |
S-100 |
0/1(breast)1, 0/1(common
bile duct)6,
0/1(base
of skull, malignant)7,
0/1(subcutis
over knee, malignant)8,
0/1(malignant
rectovaginal tumour: biphasic tumour composed of spindle cell
and epithelioid components)9,
0/1(uterus)10, 8/24(>50%
of cells: 2 cases, 25-50% of cells: 3 cases, 5-25% of cells: 3
cases)12 |
HMB45 |
1/1(breast)1, 1/1(pancreas)3, 1/1(uterus)4, 4/4(2
rectum, 1 heart, 1 perineum)5,
1/1(common
bile duct)6,
1/1(base
of skull, malignant, scattered cells positive)7,
1/1(subcutis
over knee, malignant: strong diffuse positivity)8,
1/1(malignant
rectovaginal tumour: biphasic tumour composed of spindle cell
and epithelioid components: both components positive)9, 1/1(uterus)10, 22/24(>50%
of cells: 9 cases, 25-50% of cells: 5 cases, 5-25% of cells: 8
cases)12 |
Melan-A (MART-1) |
1/1(breast)1, 0/1(common
bile duct)6,
0/1(base
of skull, malignant, equivocal staining of a few cells)7, 1/1(malignant
rectovaginal tumour: biphasic tumour composed of spindle cell
and epithelioid components: both components positive)9, 13/18(>50%
of cells: 1 case, 25-50% of cells: 5 cases, 5-25% of cells: 7
cases)12 |
Co-expression
of (HBM45 or Melan-A) and SMA |
20/2412 |
MiTF |
9/18(>50%
of cells: 4 cases, 25-50% of cells: 2 cases, 5-25% of cells: 3
cases)12 |
TFE3 |
5/17(>50%
of cells: 3 cases, 25-50% of cells: 2 cases)12 |
NKI/C3 |
1/1(malignant
rectovaginal tumour: biphasic tumour composed of spindle cell
and epithelioid components: both components positive)9 |
KBA.62 |
0/1(malignant
rectovaginal tumour: biphasic tumour composed of spindle cell
and epithelioid components: both components negative)9 |
Oestrogen receptor |
0/1(breast)1, 1/1(malignant
rectovaginal tumour: biphasic tumour composed of spindle cell
and epithelioid components)9,
0/1(uterus)10 |
Progesterone receptor |
1/1(breast)1, 0/1(malignant
rectovaginal tumour: biphasic tumour composed of spindle cell
and epithelioid components)9,
1/1(uterus)10 |
EMA |
0/1(breast)1, 0/1(common
bile duct)6,
0/1(base
of skull, malignant)7,
0/1(malignant
rectovaginal tumour: biphasic tumour composed of spindle cell
and epithelioid components)9 |
Vimentin |
0/1(breast)1, 0/1(common
bile duct)6,
0/1(base
of skull, malignant, equivocal staining of a few cells)7, 1/1(uterus)10, 12/14(>50%
of cells: 10 cases, 25-50% of cells: 2 cases)12 |
NSE |
0/1(breast)1, 0/1(pancreas)3, 1/1(common
bile duct)6,
0/1(base
of skull, malignant)7 |
Chromogranin A |
0/1(breast)1, 0/1(pancreas)3, 0/1(common
bile duct)6,
0/1(base
of skull, malignant)7,
0/1(malignant
rectovaginal tumour: biphasic tumour composed of spindle cell
and epithelioid components)9 |
Synaptophysin |
0/1(breast)1, 0/1(common
bile duct)6,
0/1(base
of skull, malignant)7 |
Neu-N |
0/1(base
of skull, malignant)7 |
CEA |
0/1(breast)1, 0/1(base
of skull, malignant)7,
0/1(malignant
rectovaginal tumour: biphasic tumour composed of spindle cell
and epithelioid components)9 |
CD10 |
1/1(malignant
rectovaginal tumour: biphasic tumour composed of spindle cell
and epithelioid components: both components strongly positive)9 |
CD31 |
0/1(breast)1 |
CD34 |
0/1(breast)1, 0/1(subcutis
over knee, malignant)8,
0/1(malignant
rectovaginal tumour: biphasic tumour composed of spindle cell
and epithelioid components)9,
0/1(uterus)10, 0/712 |
CD45 |
0/1(base
of skull, malignant)7,
0/1(subcutis
over knee, malignant)8 |
|
CD99 |
1/1(base
of skull, malignant)7 |
|
CD117 |
1/1(malignant
rectovaginal tumour: biphasic tumour composed of spindle cell
and epithelioid components)9,
1/1(uterus)10, 1/20(
25-50% of cells)12 |
|
Alpha-fetoprotein |
0/1(base
of skull, malignant)7 |
|
Placental
alkaline phosphatase |
0/1(base
of skull, malignant)7 |
|
b-HCG |
0/1(base
of skull, malignant)7 |
|
p16 |
0/1(uterus)10 |
|
| |
Site |
Differential |
distinguishing features |
|
General |
clear cell carcinoma, glycogen-rich |
cytokeratin positive, HMB-45 negative |
clear cell carcinoma, lipid-rich |
cytokeratin positive, HMB-45 negative |
metastatic melanoma |
HMB-45 positive |
Abdomen |
GIST:
PEComa may be CD117+ |
|
Kidney |
renal
clear cell carcinoma |
cytokeratin positive, HMB-45 negative |
Breast |
clear cell adenomyoepithelioma |
cytokeratin, actin and S-100 positive,
HMB-45 negative |
Breast |
clear cell myoepithelioma |
cytokeratin, actin and S-100 positive,
HMB-45 negative |
Base of skull |
chordoma, chondrosarcoma, meningioma,
pituitary adenoma, haemangioblastoma |
|
Soft tissues |
clear cell sarcoma of soft tissue |
S-100 positive |
clear cell rhabdomyosarcoma |
desmin, myogenin, myoD1 positive |
alveolar
soft part sarcoma |
PAS positive |
| |